DOCSLIB.ORG

2020 Deal-Making Roundup

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2020 Deal-Making Roundup 2020 Deal-Making Roundup WHITEPAPER Maureen Riordan, Senior Deals Analyst, Biomedtracker Deanna Kamienski, Senior Deals Analyst, Biomedtracker Introduction Against a backdrop of unprecedented disruption, medtech market also showed a strong pandemic the biopharma and medtech industries reached influence in overall deal-making activity, in incredible heights for deal-making activity during particular featuring in vitro diagnostics for SARS- 2020. This was partly necessitated by the acute CoV-2 and companies in the digital health space. need to advance COVID-19 therapeutics and diagnostics as quickly as possible, requiring large This report provides an overview of alliance, amounts of capital and shared expertise. The merger and acquisition, and financing deal activity other driving factor was the buoyancy of capital across the worldwide biopharma, medical device, markets, as investors actively sought drug- and and in vitro diagnostics industries during 2020 as device-maker opportunities, previously thought of reported by Biomedtracker. The overall data are as defensive holdings. presented across deal types, therapy areas, and payment or financing structures. The top deals In total, biopharma companies signed over 1,000 by dollar value in each space are closely detailed. alliances in 2020, with one in five related to Note that potential deal value (PDV) is defined COVID-19 assets. $130bn was exchanged in M&A as the sum of disclosed up-front payment(s) activities in the sector, while overall financing for plus any announced or received pre- or post- the year steadily increased quarter-on-quarter for commercialization milestone payment(s). a total of over $140bn. The comparably smaller 2 / March 2021 © Informa UK Ltd 2021 (Unauthorized photocopying prohibited.) Biopharma Alliances Biopharma alliances for 2020 reached a total to quarter; except for a slight dip during Q3, the potential deal value of $186.7bn from 1,087 aggregate deal value mostly followed the same completed transactions [Figure 1]. Throughout trajectory. Of the 362 deals with disclosed values, the year, deal volume steadily increased quarter 54 topped the billion-dollar mark. Figure 1. 2020 biopharma deal volume and value distributions, by quarter 0 2 0000 2 00 22 0000 20 21 0000 200 0000 10 ea oume 20000 100 10000 0 ota ea aue (Um) 0 0 1 2 Q3 Q4 ea ota ea aue Source: Biomedtracker, February 2021 In the largest alliance of the year, Merck KGaA and commercialization. Artios originally licensed and Artios Pharma partnered in a global three- the DDR IP from Cancer Research Technology in year strategic research collaboration, worth up 2016. The Merck KGaA partnership will support to $6.9bn, to jointly identify multiple synthetic advancement of Artios’s other DDR pipeline lethal targets for up to eight oncology drug projects into the clinic, including lead programs, targets associated with DNA damage response inhibitors of Pol-theta (solid tumors) and ATR (DDR) processes [Table 1]. Artios could also (targeting cancer; in-licensed from MD Anderson see up to $860m in total milestones per target. Cancer Center and ShangPharma in 2019), which Artios has opt-in rights for joint development are specifically excluded from the collaboration. © Informa UK Ltd 2021 (Unauthorized photocopying prohibited.) March 2021 / 3 Table 1. Top 10 2020 biopharma alliances, by potential deal value Potential Deal Royalty Licensee Licenser Products/Technologies Deal Value Date Range ($m) Artios’s nuclease-targeting discovery platform to jointly identify multiple synthetic lethal targets for precision Artios oncology drug candidates; Merck adds experience and Double- Feb. 27 Merck KGaA 6,910 Pharma resources in the field of DNA Damage Response and digits has the right to opt into exclusive development and commercialization of compounds on up to eight targets Joint development and commercialization of Daiichi’s DS- Daiichi 1062 (in Phase I for non-small cell lung cancer and triple- Jul. 27 AstraZeneca 6,000 NA Sankyo negative breast cancer) globally, excluding Japan where Daiichi retains exclusive rights Global development and commercialization (on a co- Seattle Sep. 14 Merck & Co. exclusive basis) of Seattle Genetics’ ladiratuzumab vedotin, 4,200 NA Genetics which is in Phase II for breast cancer and other solid tumors Silence’s GalNAc-siRNA platform to discover and develop High-single Silence initially five siRNA targets in cardiovascular, renal, metabolic, to low- Mar. 25 AstraZeneca 4,080 Therapeutics and respiratory diseases; AZ has option to extend to double another five targets digits Janssen contributes proprietary antigen-binding domains for up to four tumor-associated antigen targets; Fate will Double- Fate Apr. 2 Janssen Biotech apply its iPSC platform to research and preclinically develop 3,916 digits to Therapeutics new chimeric antigen receptor (CAR) NK and CAR T-cell mid-teens cancer immunotherapies Joint global development and commercialization of Genmab’s DuoBody-CD3xCD20 (epcoritamab; GEN3013), DuoHexaBody-CD37 (GEN3009), and DuoBody-CD3x5T4 (GEN1044); discovery collaboration Jun. 10 AbbVie Genmab combining Genmab’s DuoBody technology and 3,900 22–26% AbbVie’s payload and antibody-drug conjugate platform for up to four additional differentiated next- generation antibody candidates, potentially across both solid tumors and hematological malignancies Undisclosed firm gets global rights to develop and Top 10 commercialize multiple products in combination with undisclosed Jun. 24 Alteogen Alteogen’s recombinant human hyaluronidase enzyme 3,881 NA pharma ALT-B4, derived using its Hybrozyme protein engineering company technology Sage’s zuranolone (SAGE-217) for major depressive disorder, postpartum depression and other psychiatric disorders, and SAGE-324 for essential tremor and other neurological High-teens Sage Nov. 24 Biogen disorders; in the US, both firms will jointly develop and 3,125 to low- Therapeutics commercialize, while Biogen gets exclusive rights to develop twenties and commercialize the compounds outside the US, except in Japan, Taiwan, and South Korea Repare’s CRISPR-enabled genome-wide synthetic lethal Bristol Myers Repare target discovery platform, SNIPRx, to jointly identify May 26 3,065 Undisclosed Squibb Therapeutics multiple synthetic lethal precision oncology targets for drug candidates IDEAYA’s synthetic lethality programs MAT2A (IDE397), Pol High-single IDEAYA Theta (POLQ), and Werner Helicase (WRN), which have to sub-teen Jun. 16 GlaxoSmithKline 3,030 Biosciences potential applicability in lung, prostate, breast, colorectal, double- and ovarian cancer digits Source: Biomedtracker, February 2021 4 / March 2021 © Informa UK Ltd 2021 (Unauthorized photocopying prohibited.) For 2020 overall, alliances including an announced alliance to globally develop and commercialize milestone component dominated over up-front (on a co-exclusive basis) Seattle Genetics’ payments in deal structures. This portion of ladiratuzumab vedotin, an investigational partnerships accounted for 75% of the aggregate antibody-drug conjugate (ADC) targeting LIV- deal value in those 362 deals with disclosed PDVs 1, in Phase II for breast cancer and other solid [Figure 2]. There were 41 deals in all with potential tumors. SG gets up front $600m and a $1bn future payments of more than a billion dollars, equity investment through Merck’s purchase of SG led by Merck KGaA’s December 2020 partnership common stock at $200 per share (a 32% premium) with Artios. US-headquartered Merck & Co (not to and could also see up to $2.6bn in milestone be confused with German Merck KGaA) paid the payments ($850m development, $1.75bn sales). highest up-front payment of 2020 in a September Figure 2. 2020 biopharma alliance deal breakdown, by payment type 0000 0000 0000 20000 2 12 10000 1 22 ota ea aue (Um) 000 1 4,754 7,665 5,384 0 1 2 Q3 Q4 Upfront ietone Source: Biomedtracker, February 2021 © Informa UK Ltd 2021 (Unauthorized photocopying prohibited.) March 2021 / 5 Oncology was the most active therapeutic infectious disease (with 273 deals making up 25% area for partnering during 2020, with 386 of all of the total), and neurology/psychiatry, with 120 partnerships (36%) having at least one cancer alliances or 11% of the aggregate. asset [Figure 3]. Oncology was followed by Figure 3. 2020 biopharma alliances across therapy area, by deal volume Oncology 386 (36%) Infectious disease 273 (25%) Neurology/Psychiatry 120 (11%) Other* 100 (9%) Autoimmune/immunology 75 (7%) Not Specified 70 (6%) Ophthalmology 45 (4%) Cardiovascular 40 (4%) Endocrine 35 (3%) Metabolic 32 (3%) 0 50 100 150 200 250 300 350 400 450 Number of alliance deals (% of total) Note: Deals involving more than one asset or therapy area may be counted multiple times; cumulative percentages will therefore exceed 100%. *Includes allergy, dermatology, ENT/dental, gastroenterology, hematology, obstetrics/gynecology, orthopedics, renal, rheumatology, and urology. Source: Biomedtracker, February 2021 6 / March 2021 © Informa UK Ltd 2021 (Unauthorized photocopying prohibited.) Not surprisingly, oncology deals also made up in depression and movement disorders. Biogen the greatest percentage (49%) of aggregate also did large neuro-focused deals with Sangamo potential 2020 deal value, with $91.6bn [Figure Therapeutics ($2.7bn) for up to 12 CNS programs, 4]. Next was neurology/psychiatry, which fetched and Denali Therapeutics ($2.2bn) for Parkinson’s $36.4bn in aggregate PDV (20% of the 2020 and other neurodegenerative diseases. Deals for total). The top deal
Load more

Recommended publications
  • BC's $25 Billion Opportunity a Transformation Agenda
    BC's $25 Billion Opportunity A Transformation Agenda UPDATED MARCH 2020 2 BC TECH Policy Recommendations 11 Key Policy Recommendations SCALE TALENT OUTCOME: OUTCOME: ScaleUp BC's Tech Companies and increase Increase the tech talent pool to fulfill BC’s Technology Adoption in every industry. enormous economic growth potential. RECOMMENDATIONS RECOMMENDATIONS 1. 1. Partner with the federal government to Fund an additional 2,000 tech-relevant public invest a total of $50M over 5 years in ScaleUp post-secondary graduates to meet industry BC, a partnership to drive economic growth demand. and competitiveness across BC. 2. 2. Make the federal Global Talent Stream (GTS) per- Create a BC Transformation Fund of $1B over ten manent and extend the up-front BC foreign buyers’ years to accelerate BC's transition to the economy housing tax exemption to GTS nominees to ensure of the future. fairness. Extend the BC Provincial Nominee Program (PNP) Tech Pilot and increase the allocation of PNP 3. places for BC to unlock additional talent supply. Strengthen and extend DataBC’s mandate to stra- tegically manage BC’s public data to accelerate plat- 3. form growth and improve access to data. Establish a labour credit of 10% of the starting salary of a returning Canadian worker (resident for 3 years) re- 4. fundable against the payroll tax liabilities of BC-head- Update refundable SR&ED and Industrial Research quartered tech companies to bring Canadians working Assistance Program (IRAP) ceiling and employee lim- abroad home. its to increase these programs' scaling power. 4. 5. Double the New Ventures BC Innovator Skills Initiative Introduce a superdeduction for 150% of qualifying co-op places, increase the program employee cap from tech commercialization costs for BC-headquartered 100 to 300, and expand the program to include workers tech companies to promote market success and transitioning to tech to increase work-integrated learn- scale-up.
    [Show full text]
  • Debates of the House of Commons
    43rd PARLIAMENT, 2nd SESSION House of Commons Debates Official Report (Hansard) Volume 150 No. 086 Thursday, April 22, 2021 Speaker: The Honourable Anthony Rota CONTENTS (Table of Contents appears at back of this issue.) 5997 HOUSE OF COMMONS Thursday, April 22, 2021 The House met at 10 a.m. government's position on it, diplomatic representations it has made with respect to that issue, as well as the government's intention with respect to raising the genocide investigation specifically. Prayer The response that was tabled to that question makes no mention of any genocide investigation. In fact, it does not address the ques‐ tion at all. It refers broadly to Sri Lanka, but it makes no mention of ROUTINE PROCEEDINGS the substance of the question. I know that it is practice for the Speaker not to be asked to evalu‐ ● (1005) ate the particulars of the quality of the response. However, in this [English] case, given that the alleged response does not in any way acknowl‐ COMMISSIONER OF THE ENVIRONMENT AND edge or respond to the question, I would submit that this makes a SUSTAINABLE DEVELOPMENT total mockery of the expectation in the Standing Orders for the gov‐ The Speaker: It is my duty to lay upon the table, pursuant to ernment to table a response. subsection 23(5) of the Auditor General Act, the spring 2021 re‐ There have to be some constraints on the response the govern‐ ports of the Commissioner of the Environment and Sustainable De‐ ment presents. After all, if the government were to present a re‐ velopment to the House of Commons.
    [Show full text]
  • BC's Tech Sector BC Tech Members by Stage
    Year in Review 2020–2021 Year in Review | 2020-2021 BC Tech Members by Stage Technology Impact BC Tech members employ over 105,000 people in BC and Awards Finalists more globally Spirit of BC Tech – Resilience Copperleaf PressReader Seaspan Shipyards Thrive Health Startup Growth Traction on Demand Revenue: Up to $1M Revenue: $1M-$10M Excellence in Technology Innovation Employees: 1-9 Employees: 10-49 Canexia Health Dapper Labs, Inc. FORM 25% 30% TraceSafe Technologies Inc. Excellence in Technology Adoption Advanced Intelligent Systems Boast.ai HSBC Global Services Canada Limited (HGCA) Limage Media Group | Give + Share Humanitarian Scale Anchor Software Revenue: $10M-$50M Revenue: $50M+ Company of the Year – Startup Employees: 50-199 Employees: 200+ ehsAI Ideon Technologies Live It Earth 22% 23% Matidor.com Company of the Year – Growth Acuva Technologies Inc. Launchpad Technologies Inc. PrecisionOS Technology BC's Tech Sector Riipen Company of the Year – Export Boast.ai Tech Companies GeoComply Solutions Inc Invinity Energy Systems by region 177 LMI Technologies Company of the Year – Scale Canalyst Northeast 120 East Side Games Jane Software Inc Thinkific North Coast & Nechako Company of the Year – Anchor Cariboo 150 AbCellera Absolute Software 912 Cymax Group Thompson-Okanagan WELL Health Technologies Corp. Kootenay Tech Culture of the Year Freightera 7637 240 Klue Lower Mainland SW Lumen5 Rival Technologies Vancouver Island & Coast 1630 Game Changer Diversity & Inclusion Broadband TV Clio East Side Games STEMCELL Technologies Person of
    [Show full text]
  • Fidelity® Nasdaq Composite Index® Fund
    Fidelity® Nasdaq Composite Index® Fund Semi-Annual Report May 31, 2021 Contents Note to Shareholders 3 Investment Summary 4 Schedule of Investments 6 Financial Statements 85 Notes to Financial 89 Statements Shareholder Expense 97 Example Board Approval of 98 Investment Advisory Contracts and Management Fees Liquidity Risk 106 Management Program To view a fund’s proxy voting guidelines and proxy voting record for the 12-month period ended June 30, visit http://www.fidelity.com/proxyvotingresults or visit the Securities and Exchange Commission’s (SEC) web site at http://www.sec.gov. You may also call 1-800-544-8544 to request a free copy of the proxy voting guidelines. Nasdaq®, OMX®, NASDAQ OMX®, Nasdaq Composite®, and The Nasdaq Stock Market®, Inc. are registered trademarks of The NASDAQ OMXGroup, Inc. (which with its Affiliates are the Corporations) and are licensed for use by Fidelity. The product has not been passed on by the Corporations as to its legality or suitability. The product is not issued, endorsed or sold by the Corporations. The Corporations make no warranties and bear no liability with respect to shares of the product. Standard & Poor’s, S&P and S&P 500 are registered service marks of The McGraw-Hill Companies, Inc. and have been licensed for use by Fidelity Distributors Corporation. Other third-party marks appearing herein are the property of their respective owners. All other marks appearing herein are registered or unregistered trademarks or service marks of FMR LLC or an affiliated company. © 2021 FMR LLC. All rights reserved. This report and the financial statements contained herein are submitted for the general information of the shareholders of the Fund.
    [Show full text]
  • Vancouver Cross-Border Investment Guide
    Claire to try illustration idea as one final cover option Vancouver Cross-Border Investment Guide Essential legal, tax and market information for cross-border investment into Vancouver, Canada Digital Download 1 Vancouver Cross-Border Contents Investment Guide Published October 2020 Version 1.2, released January 2021 Why Invest in Vancouver ............................................................................1 Sectors to Watch ........................................................................................... 3 About the Vancouver Economic Commission Technology ..................................................................................................3 The Vancouver Economic Commission (VEC) serves one of the world’s fastest-growing, low- Cleantech .................................................................................................... 4 carbon economies. As the economic development agency for the city’s businesses, investors and citizens, VEC works to strengthen Vancouver’s economic future by supporting local companies, attracting high-impact investment, conducting and publishing leading-edge industry research, Media and Entertainment ............................................................................5 and promoting international trade. VEC works collaboratively to position Vancouver as a global destination for innovative, creative, diverse and sustainable development. Life Sciences ............................................................................................... 6 VEC respectfully
    [Show full text]
  • Fidelity® Nasdaq Composite Index® Fund
    Quarterly Holdings Report for Fidelity® Nasdaq Composite Index® Fund February 28, 2021 EIF-QTLY-0421 1.814098.116 Schedule of Investments February 28, 2021 (Unaudited) Showing Percentage of Net Assets Common Stocks – 99.7% Shares Value COMMUNICATION SERVICES – 16.7% Diversified Telecommunication Services – 0.2% Alaska Communication Systems Group, Inc. 34,501 $ 112,818 Anterix, Inc. (a) 7,844 331,252 ATN International, Inc. 7,220 351,470 Bandwidth, Inc. (a) (b) 12,082 1,913,306 Cogent Communications Group, Inc. (b) 25,499 1,526,115 Consolidated Communications Holdings, Inc. (a) 21,768 114,500 Iridium Communications, Inc. (a) 77,117 2,954,352 Liberty Global PLC: Class A (a) 112,326 2,766,028 Class B (a) 327 7,521 Class C (a) 204,417 4,967,333 Liberty Latin America Ltd.: Class A (a) 17,405 190,933 Class C (a) 105,781 1,159,360 ORBCOMM, Inc. (a) 54,925 419,078 Radius Global Infrastructure, Inc. (a) (b) 37,222 460,808 Sify Technologies Ltd. sponsored ADR (a) (b) 7,275 22,916 Vonage Holdings Corp. (a) 142,421 1,882,806 19,180,596 Entertainment – 2.5% Activision Blizzard, Inc. 429,734 41,086,868 Bilibili, Inc. ADR (a) (b) 99,200 12,496,224 Blue Hat Interactive Entertainment Technology (a) (b) 13,117 16,659 Chicken Soup For The Soul Entertainment, Inc. (a) 2,009 51,370 Cinedigm Corp. (a) 73,305 102,627 CuriosityStream, Inc. Class A (a) 24,573 426,833 DouYu International Holdings Ltd. ADR (a) 82,330 1,180,612 Electronic Arts, Inc.
    [Show full text]
  • Mid-Year 2020 Metro Vancouver Office Market Report
    Mid-Year 2020 Office Market Report Metro Vancouver, BC metro Vancouver Pandemic impact fails to materialize as downtown vacancy & absorption trends Vacancy Rate remains tight amid record-low suburban vacancy 0.0% 2.0% 4.0% 6.0% 8.0% 10.0% 12.0% 14.0% redictions that the impacts from a global mid-year 2019, but was still less than the 5.1% 366,304 Ppandemic would fundamentally alter recorded just 24 months ago. Regional vacancy 2020F 4% the dynamics of Metro Vancouver’s office is forecasted to decline to 4% by year-end market failed to materialize at mid-year 2020 2020 due to a profound lack of new supply -26,019 as vacancy in the suburbs reached record both downtown and in the suburbs as well Mid-2020 4.7% 7.3% lows and downtown Vancouver continued to as a strong track record of preleasing. The post one of the tightest office vacancy rates latter helps insulate against notable spikes in 478,555 vacancy when new supply is added and force 2019 4.4% in North America despite an initial wave of sublease vacancy. New office development many existing businesses to consider existing activity throughout the region remained on head lease space or, at least in the case of 2018 5.1% 1,802,623 schedule with only minor delays due in large downtown Vancouver, the rising availability of part to the provincial government designating sublease opportunities. Downtown Vancouver construction as an essential service in its and, to a lesser extent, the suburbs, were 2017 8% 1,223,656 initial response to COVID-19 in March 2020.
    [Show full text]
  • Undergraduate Degree Programs in Physics and Astronomy 12:40
    Beyond First Year: Undergraduate Degree Programs in Physics and Astronomy 12:40 – 13:45, Thursday March 14, 2018 Hennings 202 Sandwiches and drinks will be served 12:40 Colin Gay, Department Head and Salena Li, Undergraduate Coordinator - Introduction to the Department 12:45 Chris Waltham, Undergraduate Chair 0 12:55 Janis McKenna, 2nd-4th Year Advisor 1 13:00 Vesna Sossi, Biophysics Program Chair 2 13:05 Ingrid Stairs, Astronomy Program Chair 3 13:10 Javed Iqbal, Science Coop Program Director 4 Club activities 13:20 Physsoc – Ella Meyer 5 13:25 Astronomy – Katie Rink 6 13:30 Biophysics – Chantal Percival 7 QUESTION Period Physics is Hard So why do it? • Because you love it • Because you want to know how things work • Because you want to know how the Universe works • Because it opens up a wide variety of career opportunities What can you do with a physics degree? What can you do with a physics degree? Online Physics and Astronomy (PHAS) Graduate Survey • 235 participants • Most participants graduated in the last decade, with a few much earlier. • Careers 30% PHAS, 40% PHAS-related, 30% unrelated to PHAS. • Highest PHAS degree is a B.Sc. – 43% Which aspects of your studies have been most relevant to your career? More than 80% of respondents declared all of these as “Very Important” or “Important”: • Assessing the value of information critically • Learning on your own • Speaking clearly/effectively • Writing clearly/effectively • Working with others • Using computers • Solving numerical problems • Research experience • Managing projects UBC PHAS B.Sc grads in non- Law • Partner, McMillan LLP academic/teaching work • Barrister & Solicitor Manager Administrators • Technical project manager, D-Wave • Program Administrator, Canadian Mental Health • Business Development Lead at Abcellera, a UBC start-up Association Military Airline • Pilot, RCAF • Pilot • Ottawa/Defence Scientist Consultants Owner/President • Dubin Environmental • Owner of Murray Johnson Engineering Ltd.
    [Show full text]
  • Abcellera Biologics Inc. (Exact Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39781 AbCellera Biologics Inc. (Exact name of Registrant as specified in its Charter) British Columbia Not Applicable (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 2215 Yukon Street V5Y 0A1 Vancouver, BC (Address of principal executive offices) Registrant’s telephone number, including area code: (604) 559-9905 Securities registered pursuant to Section 12(b) of the Act: Trading Title of each class Symbol(s) Name of each exchange on which registered Common shares, no par value per share ABCL The Nasdaq Stock Market Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES ☐ NO ☒ Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. YES ☐ NO ☒ Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Investors Embraced Big Risks in a Wild Quarter for Trading
    P2JW091000-5-A00100-17FFFF5178F ***** THURSDAY,APRIL 1, 2021 ~VOL. CCLXXVII NO.75 WSJ.com HHHH $4.00 DJIA 32981.55 g 85.41 0.3% NASDAQ 13246.87 À 1.5% STOXX 600 429.60 g 0.2% 10-YR. TREAS. g 7/32 , yield 1.749% OIL $59.16 g $1.39 GOLD $1,713.80 À $29.90 EURO $1.1732 YEN 110.72 Tumultuous Times Biden What’s Meme stocks, SPACs and a fire sale fuel dramatic start to 2021. Unveils News Performanceinthe first quarter DowJones Industrial Average 8% Public Business&Finance Works inancial markets went 6 Fintooverdriveinthe firstquarter,with investors Package large and small embracing Nasdaq risk and driving aturbulent 4 Composite start to the year. A1, B7 Index President’s $2.3 trillion The Dow industrials gained 7.8% during the proposal would boost quarter,while the S&P 500 2 corporate taxes to pay climbed 5.8% and the Nas- daq added 2.8%. B13 for roads, research Micron Technologyand 0 BY ANDREW RESTUCCIA Western Digital areeach ex- AND TARINI PARTI ploring apotential deal for Kioxia that could value the President Biden unveiled a Japanese semiconductor com- –2 Jan. Feb. March $2.3trillion infrastructureplan panyatabout $30 billion. A1 centered on fixing roads and Huaweisuffered ararede- Year-to-dateperformancecompared to the S&P500 10-yearTreasury yield CBOE Volatility Index bridges, expanding broadband cline in revenue during the GameStop ARK Innovation ETF Viacom internet access and boosting fourth quarter last year,as funding forresearch and devel- 1,500% 20% 150% 2.0% 40 U.S. sanctions hammered its opment, plus higher corporate businessand sales outside of taxestopay forthe package.
    [Show full text]
  • Holdings As of June 30, 2021
    Units Cost Market Value INTERNATIONAL EQUITY FUND-I International Equities 97.27% International Common Stocks AUSTRALIA ABACUS PROPERTY GROUP 4,781 10,939 11,257 ACCENT GROUP LTD 3,078 2,769 6,447 ADBRI LTD 224,863 495,699 588,197 AFTERPAY LTD 18,765 1,319,481 1,662,401 AGL ENERGY LTD 3,897 48,319 23,926 ALTIUM LTD 11,593 214,343 319,469 ALUMINA LTD 10,311 14,655 12,712 AMP LTD 18,515 29,735 15,687 APA GROUP 2,659 20,218 17,735 APPEN LTD 20,175 310,167 206,065 ARENA REIT 2,151 5,757 5,826 ASX LTD 678 39,359 39,565 ATLAS ARTERIA LTD 5,600 25,917 26,787 AURIZON HOLDINGS LTD 10,404 32,263 29,075 AUSNET SERVICES LTD 9,482 10,386 12,433 AUSTRALIA & NEW ZEALAND BANKIN 22,684 405,150 478,341 AVENTUS GROUP 2,360 4,894 5,580 BANK OF QUEENSLAND LTD 2,738 17,825 18,706 BEACH ENERGY LTD 5,466 6,192 5,108 BEGA CHEESE LTD 1,762 6,992 7,791 BENDIGO & ADELAIDE BANK LTD 2,573 19,560 20,211 BHP GROUP LTD 9,407 243,370 341,584 BHP GROUP PLC 75,164 1,584,327 2,212,544 BLUESCOPE STEEL LTD 2,905 24,121 47,797 BORAL LTD 4,848 16,859 26,679 BRAINCHIP HOLDINGS LTD 5,756 2,588 2,112 BRAMBLES LTD 153,566 1,133,082 1,318,725 BRICKWORKS LTD 375 4,689 7,060 BWP TRUST 2,988 8,177 9,530 CARSALES.COM LTD 466 6,896 6,916 CENTURIA INDUSTRIAL REIT 2,943 6,264 8,191 CENTURIA OFFICE REIT 190,589 261,156 334,222 CHALICE MINING LTD 464 3,129 2,586 CHALLENGER LTD 3,038 15,904 12,335 CHARTER HALL LONG WALE REIT 3,600 12,905 12,793 CHARTER HALL RETAIL REIT 148,478 395,662 422,150 CHARTER HALL SOCIAL INFRASTRUC 2,461 5,340 6,404 CIMIC GROUP LTD 409 6,668 6,072 COCHLEAR LTD 2,492
    [Show full text]
  • Stoxx® Global 3000 Ex Uk Index
    STOXX® GLOBAL 3000 EX UK INDEX Components1 Company Supersector Country Weight (%) Apple Inc. null null 3.21 Microsoft Corp. null null 3.03 Amazon.com Inc. null null 2.30 FACEBOOK CLASS A null null 1.23 ALPHABET CLASS C null null 1.21 TSMC null null 0.82 TESLA null null 0.75 NVIDIA Corp. null null 0.72 JPMorgan Chase & Co. null null 0.70 Johnson & Johnson null null 0.66 VISA Inc. Cl A null null 0.61 Berkshire Hathaway Inc. Cl B null null 0.58 UnitedHealth Group Inc. null null 0.57 Samsung Electronics Co Ltd null null 0.57 NESTLE null null 0.56 PayPal Holdings null null 0.51 Home Depot Inc. null null 0.50 Procter & Gamble Co. null null 0.50 MasterCard Inc. Cl A null null 0.50 Walt Disney Co. null null 0.48 Bank of America Corp. null null 0.46 ASML HLDG null null 0.43 ADOBE null null 0.42 ROCHE HLDG P null null 0.41 Comcast Corp. Cl A null null 0.40 Exxon Mobil Corp. null null 0.40 Verizon Communications Inc. null null 0.36 NOVARTIS null null 0.36 Toyota Motor Corp. null null 0.35 Intel Corp. null null 0.35 Salesforce.com Inc. null null 0.34 Netflix Inc. null null 0.34 Cisco Systems Inc. null null 0.34 Pfizer Inc. null null 0.33 LVMH MOET HENNESSY null null 0.33 Coca-Cola Co. null null 0.32 AT&T Inc. null null 0.32 PepsiCo Inc.
    [Show full text]